Overview
This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.
Description
The study will enroll 80 patients aged 15-60 years with localized stable vitiligo. Participants will be randomized into two groups: one receiving needling and the other microneedling, each followed by NBUVB therapy. The primary outcome is the percentage of repigmentation at 12 weeks, assessed through digital planimetry and standardized clinical photography. Secondary outcomes include adverse effects such as erythema, post-inflammatory hyperpigmentation, infection, and scarring.
Eligibility
Inclusion Criteria:
- Both male and female
- Age 15-60 years
- Patients having vitiligo for more than 1 year
Exclusion Criteria:
- Patients with tendency of keloid formation or hypertrophic scarring
- Patients with any bleeding disorder, coagulation defect or using anti platelets
- Any local infection at the treatment site
- Patients who had received systemic therapy in last 6 months